DOCSLIB.ORG

Risk of Invasive Candidiasis with Prolonged Duration of ICU Stay: a Systematic Review and Meta-­Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Risk of Invasive Candidiasis with Prolonged Duration of ICU Stay: a Systematic Review and Meta-­Analysis Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-036452 on 12 July 2020. Downloaded from Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta- analysis Zhidan Zhang, Ran Zhu, Zhenggang Luan, Xiaochun Ma To cite: Zhang Z, Zhu R, ABSTRACT Strengths and limitations of this study Luan Z, et al. Risk of Objective This study aimed to evaluate the duration of invasive candidiasis with intensive care unit (ICU) stay prior to onset of invasive ► This meta- analysis is one of the few that investi- prolonged duration of ICU candidiasis (IC)/candidaemia. stay: a systematic review and gated the association of invasive candidiasis with Design Systematic review and meta- analysis. meta- analysis. BMJ Open length of intensive care unit (ICU) stay, using data Data sources PubMed, Cochrane, Embase and Web of 2020;10:e036452. doi:10.1136/ published worldwide and adhering to the Preferred Science databases were searched through June 2019 to bmjopen-2019-036452 Reporting Items for Systematic Reviews and Meta- identify relevant studies. Analyses guideline. ► Prepublication history and Eligibility criteria Adult patients who had been admitted ► Extensive subgroup analyses were performed and additional material for this to the ICU and developed an IC infection. paper are available online. To meta- regression was made to examine possible Data extraction and synthesis The following data were view these files, please visit causes of heterogeneity in the results. extracted from each article: length of hospital stay, length the journal online (http:// dx. doi. ► Although this meta-analysis was performed me- of ICU stay, duration of ICU admission prior to candidaemia org/ 10. 1136/ bmjopen- 2019- thodically, it lacked a prespecified protocol and pre- onset, percentage of patients who received antibiotics and 036452). liminary registration. duration of their antibiotic therapy prior to candidaemia ► Heterogeneity exists in some subgroup and overall Received 11 September 2019 onset, and overall mortality. In addition to the traditional analyses. Revised 12 March 2020 meta- analyses, meta- regression was performed to explore ► Due to a lack of sufficient published data, rela- Accepted 13 March 2020 possible mediators which might have contributed to the tionship between prolonged exposure to broad- heterogeneity. spectrum antibiotics and ICU-acquired candidaemia Results The mean age of patients ranged from 28 to could not be assessed. 76 years across selected studies. The pooled mean duration of ICU admission before onset of candidaemia http://bmjopen.bmj.com/ was 12.9 days (95% CI 11.7 to 14.2). The pooled mean duration of hospital stay was 36.3±5.3 days (95% CI incidence of IC has been gradually increasing 25.8 to 46.7), and the pooled mean mortality rate was in most regions,3 ranging from 0.5 to 32 cases 49.3%±2.2% (95% CI 45.0% to 53.5%). There was no per 1000 ICU admissions. It has been found significant difference in duration of hospital stay (p=0.528) or overall mortality (p=0.111), but a significant difference that there is a significant difference in the was observed in the mean length of ICU stay (2.8 days, incidence of IC among several countries in p<0.001), between patients with and without Candida Latin America and North America; however, on September 25, 2021 by guest. Protected copyright. albicans. Meta- regression analysis found that South data from Asia Pacific countries are still rela- American patients had longer duration of ICU admission tively rare.4 Candidaemia has been described prior to candidaemia onset than patients elsewhere, while as the most common manifestation of IC, those in Asia had the shortest duration. and further infection of the liver, spleen, Conclusions Patients with IC are associated with longer heart valves or eye might also occur after a ICU stay, with the shortest duration of ICU admission bloodstream infection.5 In the past, the main prior to the candidaemia onset in Asia. This shows a Candida species isolated from patients with IC © Author(s) (or their more proactive strategy in the diagnosis of IC should be employer(s)) 2020. Re- use considered in caring for ICU patients. was Candida albicans. However, non-C. albicans permitted under CC BY-NC. No species have seen a rising proportion and now commercial re- use. See rights account for approximately 50% of all cases of and permissions. Published by 1 6–8 BMJ. INTRODUCTION IC in the past two decades. Candida species account for approximately Diagnosis and management of IC remain Department of Critical Care 1 2 Medicine, The First Hospital 70%–90% of invasive fungal infections and challenging for physicians in the ICU. The of China Medical University, are the most frequent cause of fungal infec- early initiation of empiric antifungal treat- Shenyang, China tions in patients admitted to the intensive ment has been demonstrated to improve the 1 2 9 Correspondence to care unit (ICU). Invasive candidiasis (IC) is prognosis of IC. However, there is diffi- Dr Xiaochun Ma; associated with a high mortality rate (range: culty in the diagnosis of IC, which can delay XCMA2972@ sina. com 40%–60%).1 2 Over recent decades, the timely antifungal treatment.2 10 Blood culture Zhang Z, et al. BMJ Open 2020;10:e036452. doi:10.1136/bmjopen-2019-036452 1 Open access BMJ Open: first published as 10.1136/bmjopen-2019-036452 on 12 July 2020. Downloaded from remains the gold standard for the diagnosis of IC, but its sensitivity is variable (21%–71%).11 To improve the diagnosis of IC and to identify the patients who may best benefit from prophylactic, pre- emptive or empiric therapy prior to or at an early stage of ICU admission, several methods in predicting the development of IC based on their associated risk factors have been developed.12 13 The risk factors in the various predictive models include broad-spectrum antibiotic use, central venous catheter placement, total parenteral nutri- tion, haemodialysis (days 1–3 in the ICU), any surgery, immunosuppressive use, pancreatitis prior to ICU admis- sion and steroid use. However, different risk factors are included in different predictive models. In addition, potential risk factors such as Candida colonisation14 and mechanical ventilation15 have not been included in these models. Long- term ICU stay has been reported as a risk factor for IC.11 14–16 Only a few studies have examined the interval between ICU admission or initiation of broad- spectrum antibiotics and the diagnosis of IC. However, the specific duration of long- term ICU stays and the prolonged use of broad- spectrum antibiotics are often arbitrarily defined and inconsistent among studies.6 12 15 17–19 Furthermore, a large majority of severe candidiasis cases are caused Figure 1 PRISMA flow diagram of study selection. PRISMA, by endogenous colonisation. This may be the primary Preferred Reporting Items for Systematic Reviews and Meta- Analyses. reason for causing a delay of 7–10 days between exposure to risk factors and the development of IC.20 Thus, the objective of this systematic review was to editorials, case reports, proceedings, personal communi- evaluate several possible risk factors associated with the cations and case series were excluded. Studies in which development of candidaemia, including the length of patients were diagnosed with candidiasis prior to ICU hospitalisation and ICU stay, as well as regional differ- http://bmjopen.bmj.com/ admission were excluded. Studies that did not evaluate ences in these factors. the incidence of candidiasis as a primary objective or that were not designed to evaluate risk factors/prognostic factors of patients with candidiasis were also excluded. METHODS Search strategy Data extraction The study was performed in accordance with guidance The following information/data were extracted from from the Preferred Reporting Items for Systematic studies that met the inclusion criteria: name of the first Reviews and Meta- Analyses. PubMed, Cochrane, Embase author, year of publication, country, study design, type of on September 25, 2021 by guest. Protected copyright. and Web of Science databases were searched from incep- ICU, number of participants in each group, participants’ tion through June 2019 using the following terms: candi- age and gender, presence of C. albicans, presence of neut- diasis, candidemia, intensive care unit or ICU, and risk ropaenia and antifungal treatment (especially the use of factors (online supplementary table S1). Studies identi- broad- spectrum antibiotics). The following data were also fied by the search strategy were reviewed for inclusion extracted from each article: length of stay in hospital/ and data were extracted by two independent reviewers. ICU, length of stay prior to ICU admission, duration of Where there was uncertainty regarding study eligibility, ICU stay prior to candidaemia onset, antibiotic therapy a third reviewer was consulted. A flow chart of the study prior to candidaemia onset, duration of antibiotic therapy selection is shown in figure 1. prior to candidaemia onset and overall mortality. Study selection criteria Quality assessment Randomised controlled trials, cohort studies, case- We used the Risk of Bias In Non-randomized Studies of controlled and cross- sectional studies were included. All Interventions (ROBINS- I) tool to assess the quality of the studies included adult patients who were critically ill, included studies.21 ROBINS- I is based on the Cochrane who had been admitted to the ICU and who were tested Risk of Bias tool and is suited for evaluating non- positive for Candida species using blood culture analyses. randomised studies that compare the health effects of Studies had to have reported quantitative outcomes of different interventions. ROBINS-I covers seven different interest, and no author was contacted. Letters, comments, bias domains: bias due to confounding, bias in selection 2 Zhang Z, et al. BMJ Open 2020;10:e036452.
Load more

Recommended publications
  • Cidara-IFI-Infogr-12.Pdf
    ­­ ­ ­ We often think of fungal infections as simply bothersome conditions such as athlete’s foot or toenail fungus. But certain types of fungal infections, known as “ ”( ), can be dangerous and fatal. IFIs are systemic and are typically caused when fungi invade the body in various ways such as through the bloodstream or by the inhalation of spores. IFIs can also spread to many other organs such as the liver and kidney. They are associated with ­ ( ) > % ­ • Invasive candidiasis ( ) is a ­ common hospital-acquired infection in the U.S., % cases each year.v • Invasive aspergillosis () occurs most often in people with weakened immune systems or lung disease, and its prevalence is vi ­ An increasing number of people in the U.S. have putting them at greater risk for IFIs.x High-risk groups include: hospitalized patients cancer or transplant patients patients undergoing surgery patients with chronic diseases Rates of invasive candidiasis are dicult ( )is an emerging drug-resistant to estimate and can vary based on time, fungus that spreads quickly and has caused serious region, and study type. and deadly infections in over a dozen countries. + Still, it is clear that overall The CDC estimates that remain high – especially in the U.S. with invasive ix among viii ­ There is an increasingly urgent need to develop new therapies for IFIs, ­ Currently available treatments for IFIs have signicant limitations such as: • toxicities/side eects • inconsistent achievement of target drug levels • interactions with other drugs • increasing microbial resistance As the urgency around IFIs rises, multiple biopharma companies and researchers are working to develop new therapies to treat and prevent them.
    [Show full text]
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]
  • Fungal Infections – an Overview
    REVIEW Fungal infections – An overview Natalie Schellack, BCur, BPharm, PhD(Pharmacy); Jade du Toit, BPharm; Tumelo Mokoena, BPharm; Elmien Bronkhorst, BPharm, MSc(Med) School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University Correspondence to: Prof Natalie Schellack, [email protected] Abstract Fungi normally originate from the environment that surrounds us, and appear to be harmless until inhaled or ingestion of spores occurs. A pathogenic fungus may lead to infection. People who are at risk of acquiring fungal infection are those living with human immunodeficiency virus (HIV), cancer, receiving immunosuppressant therapy, neonates and those of advanced age. The management of superficial fungal infections is mainly topical, with agents including terbinafine, miconazole and ketoconazole. Oral treatment includes griseofulvin and fluconazole. Invasive fungal infections are difficult to treat, and are managed with agents including the azoles, echinocandins and amphotericin B. This paper provides a general overview of the management of fungus infections. © Medpharm S Afr Pharm J 2019;86(1):33-40 Introduction more advanced biochemical or molecular testing.4 Fungi normally originate from the environment that surrounds Superficial fungal infections us, and appear to be harmless until inhaled or ingestion of spores Either yeasts or fungi can cause dermatomycosis, or superficial occurs. Infection with fungi is also more likely when the body’s fungal infections.7 Fungi that infect the hair, skin, nails and mucosa immune system becomes weakened. A pathogenic fungus may lead to infection. The number of fungus species ranges in the can cause a superficial fungal infection. Dermatophytes are found millions and only a few species seem to be harmful to humans; the naturally in soil, human skin and keratin-containing structures, 3 ones found mostly on the mucous membrane and the skin have which provide them with a source of nutrition.
    [Show full text]
  • Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
    Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting a b,c, Alexander Lepak, MD , David Andes, MD * KEYWORDS Invasive candidiasis Pharmacokinetics-pharmacodynamics Therapy Source control Invasive fungal infections (IFI) and fungal sepsis in the intensive care unit (ICU) are increasing and are associated with considerable morbidity and mortality. In this setting, IFI are predominantly caused by Candida species. Currently, candidemia represents the fourth most common health care–associated blood stream infection.1–3 With increasingly immunocompromised patient populations, other fungal species such as Aspergillus species, Pneumocystis jiroveci, Cryptococcus, Zygomycetes, Fusarium species, and Scedosporium species have emerged.4–9 However, this review focuses on invasive candidiasis (IC). Multiple retrospective studies have examined the crude mortality in patients with candidemia and identified rates ranging from 46% to 75%.3 In many instances, this is partly caused by severe underlying comorbidities. Carefully matched, retrospective cohort studies have been undertaken to estimate mortality attributable to candidemia and report rates ranging from 10% to 49%.10–15 Resource use associated with this infection is also significant. Estimates from numerous studies suggest the added hospital cost is as much as $40,000 per case.10–12,16–20 Overall attributable costs are difficult to calculate with precision, but have been estimated to be close to 1 billion dollars in the United States annually.21 a University of Wisconsin, MFCB, Room 5218, 1685 Highland Avenue, Madison, WI 53705-2281, USA b Department of Medicine, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA c Department of Microbiology and Immunology, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA * Corresponding author.
    [Show full text]
  • Up to Date Epidemiology, Diagnosis and Management of Invasive Fungal Infections
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector EDITORIAL 10.1111/1469-0691.12642 Up to date epidemiology, diagnosis and management of invasive fungal infections I. Oren and M. Paul Infectious Diseases Institute, Rambam Health Care Campus, Bruce Rappaport Faculty of Medicine, Technion – Israely Institute of Technology, Haifa, Israel E-mail: [email protected] This issue of Clinical Microbiology and Infection is dedicated to and the presence of GVHD. However, the incidence of invasive fungal infections (IFI) based on the ESCMID confer- invasive aspergillosis is very much dependent on local epide- ence held in Rome on January 2013. The reviews summarize miology and the quality of air control in hemato-oncological the progress achieved in the fields of epidemiology, diagnosis units. Thus, in some settings, invasive aspergillosis is more and management of Candida, Aspergillus and Mucor invasive frequent than invasive candidiasis [2]. infections. Mucormycosis is the second most common invasive mould infection and its incidence increased from 0.7 per million in 1997 to 1.2 per million in 2006 [3]. In addition to immune- Epidemiology suppression, there are some unique host risk factors for mucormycosis such as diabetes keto-acidosis, burns, iron Candida spp. have become important causes of sepsis in overload and, on the other hand, deferoxamine therapy. The hospitals with incidence constantly growing over the last specific clinical syndrome of mucormycosis is associated with 20 years. Candida spp. is now the 4th most common isolate of host risk factors; thus, pulmonary mucormycosis is more bloodstream infections in many countries (and the most common in patients with hematological malignancies, while common IFI), mainly due to the increasing complexity of rhino-cerebral mucormycosis is more common in diabetic medical care [1].
    [Show full text]
  • Candida Albicans
    Zhang et al. BMC Infectious Diseases (2020) 20:126 https://doi.org/10.1186/s12879-020-4856-8 CASE REPORT Open Access Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis Ming-rui Zhang1, Fei Zhao2, Shuang Wang1, Sha Lv1, Yan Mou1, Chun-li Yao1, Ying Zhou1 and Fu-qiu Li1* Abstract Background: More and more azole-resistant strains emerged through the development of acquired resistance and an epidemiological shift towards inherently less susceptible species. The mechanisms of azoles resistance of Candida albicans is very complicated. In this study, we aim to investigate the mechanism of azole-resistant C. albicans isolated from the oral cavity of a patient with chronic mucocutaneous candidiasis (CMC). Case presentation: CMC diagnosis was given based on clinical manifestations, laboratory test findings and gene sequencing technique. Minimum inhibitory concentration (MIC) of the fungal isolate, obtained from oral cavity termed as CA-R, was obtained by in vitro anti-fungal drugs susceptibility test. To further investigate the resistant mechanisms, we verified the mutations of drug target genes (i.e. ERG11 and ERG3) by Sanger sequencing, and verified the over-expression of ERG11 and drug efflux genes (i.e. CDR1 and CDR2) by RT-PCR. A heterozygous mutation of c.1162A > G resulting in p.K388E was detected in STAT1 of the patient. The expression of CDR1 and CDR2 in CA-R was 4.28-fold and 5.25-fold higher than that of type strain SC5314, respectively. Conclusions: Up-regulation of CDR1 and CDR2 was mainly responsible for the resistance of CA-R.
    [Show full text]
  • CDHO Factsheet Oral Candidiasis
    Disease/Medical Condition CANDIDIASIS Date of Publication: May 7, 2014 (also known as “candidosis” and “moniliais”; and “thrush”; usually caused by overgrowth of yeast fungus Candida albicans, but occasionally by other species of Candida) Is the initiation of non-invasive dental hygiene procedures* contra-indicated? No Is medical consult advised? ......................................... Yes, if the candidiasis has not yet been assessed by physician or dentist for definitive diagnosis (clinically or via microscopy of scraping) and management (including potential prescription medication). Is the initiation of invasive dental hygiene procedures contra-indicated?** No Is medical consult advised? ....................................... See above. Is medical clearance required? ................................... No Is antibiotic prophylaxis required? .............................. No Is postponing treatment advised? ................................ Yes, until candidiasis has been treated and is resolved. Oral management implications Mode of transmission is contact with secretions or excretions of mouth, skin, vagina, and feces, from patients/clients or carriers; by passage from mother to baby during childbirth; and by endogenous spread. Babies with oral thrush can pass the infection to their mothers’ nipples during breast-feeding. Because Candida yeasts are normal flora of the human mouth, a positive culture does not necessarily make the diagnosis. Good oral hygiene practices can help prevent oral candidiasis in people with weakened
    [Show full text]
  • Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 May 17. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1791–1797. doi:10.1093/cid/ciy776. Estimation of direct healthcare costs of fungal diseases in the United States Kaitlin Benedict, Brendan R. Jackson, Tom Chiller, and Karlyn D. Beer Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Abstract Background: Fungal diseases range from relatively minor superficial and mucosal infections to severe, life-threatening systemic infections. Delayed diagnosis and treatment can lead to poor patient outcomes and high medical costs. The overall burden of fungal diseases in the United States is challenging to quantify because they are likely substantially underdiagnosed. Methods: To estimate total national direct medical costs associated with fungal diseases from a healthcare payer perspective, we used insurance claims data from the Truven Health MarketScan® 2014 Research Databases, combined with hospital discharge data from the 2014 Healthcare Cost and Utilization Project National Inpatient Sample and outpatient visit data from the 2005–2014 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. All costs were adjusted to 2017 dollars. Results: We estimate that fungal diseases cost more than $7.2 billion in 2017, including $4.5 billion from 75,055 hospitalizations and $2.6 billion from 8,993,230 outpatient visits. Hospitalizations for Candida infections (n=26,735, total cost $1.4 billion) and Aspergillus infections (n=14,820, total cost $1.2 billion) accounted for the highest total hospitalization costs of any disease.
    [Show full text]
  • The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches
    Journal of Fungi Review The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches Zoe Freeman Weiss 1,2,*, Armando Leon 1 and Sophia Koo 1 1 Brigham and Women’s Hospital, Division of Infectious Diseases, Boston, MA 02115, USA; [email protected] (A.L.); [email protected] (S.K.) 2 Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA 02115, USA * Correspondence: [email protected] Abstract: Invasive fungal infections are increasingly recognized in immunocompromised hosts. Current diagnostic techniques are limited by low sensitivity and prolonged turnaround times. We review emerging diagnostic technologies and platforms for diagnosing the clinically invasive disease caused by Candida, Aspergillus, and Mucorales. Keywords: fungal diagnostics; mycoses; invasive candidiasis; invasive mold infections; invasive aspergillosis; mucormycosis; transplant; immunocompromised host; non-culture diagnostics; cul- ture independent 1. Introduction In recent years, the incidence of invasive fungal infections has increased in parallel with advances in chemotherapies, immunosuppression in solid organ and hematopoietic cell transplantation, and critical care technologies. The diagnosis of invasive fungal disease Citation: Freeman Weiss, Z.; Leon, has traditionally relied on culture, direct microscopy, and histopathology. Conventional A.; Koo, S. The Evolving Landscape culture techniques are frequently insensitive, have prolonged turnaround times (TAT), of Fungal Diagnostics, Current and and may require invasive sampling. An increase in the diversity of pathogenic species Emerging Microbiological makes phenotypic identification challenging, particularly as the number of skilled clinical Approaches. J. Fungi 2021, 7, 127. mycologists declines. Precise species identification is needed given the variability of https://doi.org/10.3390/jof7020127 antifungal drug susceptibility profiles even between closely related organisms.
    [Show full text]
  • Oral Candidiasis: a Disease of Opportunity
    Journal of Fungi Review Oral Candidiasis: A Disease of Opportunity 1, 1, 1, Taissa Vila y , Ahmed S. Sultan y , Daniel Montelongo-Jauregui y and Mary Ann Jabra-Rizk 1,2,* 1 Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA; [email protected] (T.V.); [email protected] (A.S.S.); [email protected] (D.M.-J.) 2 Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA * Correspondence: [email protected]; Tel.: +1-410-706-0508; Fax: +1-410-706-0519 These authors contributed equally to the work. y Received: 13 December 2019; Accepted: 13 January 2020; Published: 16 January 2020 Abstract: Oral candidiasis, commonly referred to as “thrush,” is an opportunistic fungal infection that commonly affects the oral mucosa. The main causative agent, Candida albicans, is a highly versatile commensal organism that is well adapted to its human host; however, changes in the host microenvironment can promote the transition from one of commensalism to pathogen. This transition is heavily reliant on an impressive repertoire of virulence factors, most notably cell surface adhesins, proteolytic enzymes, morphologic switching, and the development of drug resistance. In the oral cavity, the co-adhesion of C. albicans with bacteria is crucial for its persistence, and a wide range of synergistic interactions with various oral species were described to enhance colonization in the host. As a frequent colonizer of the oral mucosa, the host immune response in the oral cavity is oriented toward a more tolerogenic state and, therefore, local innate immune defenses play a central role in maintaining Candida in its commensal state.
    [Show full text]